159 related articles for article (PubMed ID: 35945083)
1. Stereotactic Ablative Body Radiotherapy: An Emerging Weapon in the Treatment Armamentarium for Renal Cell Carcinoma or a Potential Avenue for Overtreatment?
Magee DE; Wong JK; Correa AF
Eur Urol; 2022 Dec; 82(6):623-624. PubMed ID: 35945083
[No Abstract] [Full Text] [Related]
2. Stereotactic ablative radiotherapy for primary kidney cancer.
Brown N; Breen DJ; Buckley BT; Clements W; Gangi A; Rogan C
Lancet Oncol; 2024 Jun; 25(6):e229. PubMed ID: 38821090
[No Abstract] [Full Text] [Related]
3. Stereotactic ablative radiotherapy for primary kidney cancer.
Bhargava P; Jena R; Giri RK
Lancet Oncol; 2024 Jun; 25(6):e228. PubMed ID: 38821089
[No Abstract] [Full Text] [Related]
4. Stereotactic ablative radiotherapy for primary kidney cancer - Authors' reply.
Siva S; Moon D; Pryor D
Lancet Oncol; 2024 Jun; 25(6):e230. PubMed ID: 38821091
[No Abstract] [Full Text] [Related]
5. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma.
Zalay O; Mehra P; Pereira I; Malone J; Malone S
World J Urol; 2024 Jan; 42(1):52. PubMed ID: 38244135
[TBL] [Abstract][Full Text] [Related]
6. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma.
Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S
Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777
[TBL] [Abstract][Full Text] [Related]
7. Adding Stereotactic Radiation to the Multidisciplinary Armamentarium for Localized Renal Cell Carcinoma: Ready for Primetime? : An Editorial Regarding a Recent 5-Year Efficacy and Safety Report of a Multicenter Cohort of Primary RCC Patients Treated with SABR.
Koehne EL; Psutka SP
Ann Surg Oncol; 2023 Nov; 30(12):6947-6949. PubMed ID: 37335349
[No Abstract] [Full Text] [Related]
8. The role of stereotactic ablative body radiotherapy in renal cell carcinoma: focus on oligometastatic and oligoprogressive disease.
Marandino L; Ciccarese C; Francolini G; Amparore D; Campi R;
Minerva Urol Nephrol; 2023 Apr; 75(2):260-264. PubMed ID: 36999845
[No Abstract] [Full Text] [Related]
9. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
Correa RJM; Louie AV; Staehler M; Warner A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Siva S
J Urol; 2019 Jun; 201(6):1097-1104. PubMed ID: 30741849
[TBL] [Abstract][Full Text] [Related]
10. Editorial Comment to Stereotactic body radiation therapy for kidney cancer. Where do we stand?
Goto Y
Int J Urol; 2023 May; 30(5):445-446. PubMed ID: 36852924
[No Abstract] [Full Text] [Related]
11. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.
Siva S; Kothari G; Muacevic A; Louie AV; Slotman BJ; Teh BS; Lo SS
Nat Rev Urol; 2017 Sep; 14(9):549-563. PubMed ID: 28631740
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
Siva S; Louie AV; Kotecha R; Barber MN; Ali M; Zhang Z; Guckenberger M; Kim MS; Scorsetti M; Tree AC; Slotman BJ; Sahgal A; Lo SS
Lancet Oncol; 2024 Jan; 25(1):e18-e28. PubMed ID: 38181809
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.
Zaorsky NG; Lehrer EJ; Kothari G; Louie AV; Siva S
Eur Urol Oncol; 2019 Sep; 2(5):515-523. PubMed ID: 31302061
[TBL] [Abstract][Full Text] [Related]
14. [Stereotactic body radiation therapy for primary kidney cancer].
Abancourt L; Le Guévelou J; Taillez A; Vu A; de Crevoisier R; Supiot S; Hennequin C; Chapet O; Blanchard P; Mirabel X; Lartigau É; Pasquier D
Cancer Radiother; 2023 Sep; 27(6-7):568-572. PubMed ID: 37543493
[TBL] [Abstract][Full Text] [Related]
15. Renal-cell carcinoma.
Doh L; Curtis AE; Teh BS
N Engl J Med; 2006 Mar; 354(10):1095-6; author reply 1095-6. PubMed ID: 16525153
[No Abstract] [Full Text] [Related]
16. Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002.
Montorsi F; Larcher A; Capitanio U
Eur Urol Focus; 2021 Mar; 7(2):406. PubMed ID: 31564640
[No Abstract] [Full Text] [Related]
17. Re: Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Bourillon A; Bensalah K
Eur Urol; 2024 Jul; 86(1):76. PubMed ID: 38538423
[No Abstract] [Full Text] [Related]
18. Stereotactic body radiation therapy for kidney cancer. Where do we stand?
Sosa-Fajardo P; Blanco-Suarez JM; Pineda-Munguía Á; Rubí-Olea L; Peleteiro-Higuero P; Gajate P; Zafra-Martín J; Siva S; Bossi A; López-Campos F; Couñago F
Int J Urol; 2023 May; 30(5):437-445. PubMed ID: 36746747
[TBL] [Abstract][Full Text] [Related]
19. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
20. Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S.
Paciotti M; Schmidt AL; Ravi P; McKay RR; Trinh QD; Choueiri TK
Oncologist; 2021 May; 26(5):e905-e906. PubMed ID: 33650184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
